Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis

Published 2017 View Full Article

Authors

Keywords

Direct-acting antiviral, Pangenotypic, ABT-493, ABT-530, SURVEYOR, D-alanine transaminase, Sustained virologic response, Hepatitis C, chronic, Liver cirrhosis, Interferons, Genotype

Journal

JOURNAL OF HEPATOLOGY

Volume 67, Issue 2, Pages 263-271

Publisher

Elsevier BV

Online

2017-04-13

DOI

10.1016/j.jhep.2017.03.039

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started